Fluvastatin

Evidence Level: L3

Predicted Indications: 6

Fluvastatin

Pharmacist Assessment Report

Fluvastatin: From Hyperlipidemia and Atherosclerosis to HIV Infectious Disease

One-Sentence Summary

Fluvastatin is a statin whose relations recorded in the knowledge graph relate to lipid disorders and atherosclerosis. The TxGNN model predicts it may be relevant to HIV infectious disease, but there are no registered clinical trials and 13 publications. These mostly address managing lipids in HIV patients, not treating HIV itself.

Quick Overview

Item	Content
Original Indication	Arteriosclerosis disorder, atherosclerosis, familial combined hyperlipidemia (relations recorded in the knowledge graph; the local licence records contain no indication text)
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	0.9988
Evidence Level	L3
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, fluvastatin is a statin (HMG-CoA reductase inhibitor) used for lipid disorders, and its lipid-lowering role is the basis for the relations recorded in the knowledge graph.

The literature does not propose fluvastatin as an antiviral against HIV. Instead, it supports using fluvastatin to manage dyslipidemia in HIV patients, especially those on protease inhibitors. Fluvastatin is mainly metabolised by CYP2C9 rather than CYP3A4, so it has a more favourable interaction profile with ritonavir-boosted regimens than many other statins.

Possible secondary benefits include reduced inflammation and immune activation (a statin class effect from an observational study) and protection against podocyte injury in a mouse model of HIV-associated nephropathy (preclinical). Studies in HIV/hepatitis C co-infection examined fluvastatin as an add-on to peginterferon and ribavirin and its effect on HCV replication; the data compiled for this report do not confirm the results. The prediction is therefore best read as a research question about HIV-related care, not as evidence of anti-HIV activity.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20118492	2010	Open-label randomised controlled study	J Antimicrob Chemother	Fluvastatin as an add-on to peginterferon and ribavirin in HIV/HCV genotype 1 co-infected patients
15293079	2004	Clinical trial	Infection	Fluvastatin vs pravastatin for lipid lowering in HIV patients on antiretroviral therapy, including interaction with indinavir
12351967	2002	Clinical trial	AIDS	Efficacy and safety of fluvastatin in hyperlipidaemic, protease inhibitor-treated HIV patients
16868453	2006	Randomised clinical study	AIDS	Ezetimibe lowered LDL-cholesterol by 20%, similar to fluvastatin 80 mg/day (24%) in HIV patients
19215577	2009	Pilot study	J Viral Hepat	Whether fluvastatin favours HCV replication in HIV-HCV co-infected patients
33238713	2021	Cohort	AIDS Res Hum Retroviruses	Statin use and inflammation and immune activation biomarkers in HIV patients on effective therapy (class effect)
23703578	2013	Review	Clin Pharmacokinet	Drug interactions between statins and antiviral protease inhibitors
12660532	2003	Review	AIDS	Statins and fibrates for hyperlipidaemia in HIV patients on HAART
19188342	2009	Preclinical	Nephrol Dial Transplant	Fluvastatin prevented podocyte injury in a mouse model of HIV-associated nephropathy
19838098	2010	RCT	AIDS	Rosuvastatin vs pravastatin in HIV patients on protease inhibitors (not fluvastatin, indirect)

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
123431	Lescol XL 80mg Tablet	Strip of 14 tablets	Not stated in the licence record
85524	Fluvalip 40mg Tablet	Strip of 10 tablets	Not stated in the licence record

Safety Considerations

Relations recorded in the knowledge graph (not label text): contraindication-type relations include liver disease, gallbladder disease, myopathy, muscular disease, skeletal muscle disease, familial periodic paralysis, hypotensive disorder, substance abuse/dependence, rhabdomyolysis, nodular fasciitis and injury.
Drug Interactions: 159 interactions were identified. Those rated Moderate include aprepitant, metronidazole, oxandrolone, naltrexone, nateglinide, nitisinone, rosuvastatin, simvastatin, tinidazole, glyburide and pectin. Combining fluvastatin with other statins is of particular concern. Other listed interactions have an unrated level, such as calcitriol, doxycycline, cimetidine, famotidine, acetylsalicylic acid and pantoprazole.

Please refer to the package insert for label warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: No registered trial and no study directly shows that fluvastatin treats HIV infection. The literature concerns lipid management and drug interactions in HIV patients, plus preclinical and indirect findings. The evidence level L3 reflects mainly observational data and reviews, and it should be read as a research question, not support for antiviral use.

To proceed, the following is needed:

Clarification of the research question: antiviral effect, or lipid and cardiovascular management in people living with HIV
Verification of the findings in the HIV/HCV co-infection studies
Mechanism of action data
Package insert warnings and contraindications for the marketed Indian products
A review of interaction risks with antiretroviral regimens
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.